| Sensitivity (95% CI) | Specificity (95% CI) | Positive predictive value (95% CI) | Negative predictive value (95% CI) | Area under the curve (95% CI) |
---|---|---|---|---|---|
All patients (n = 42) | |||||
FDG-PET positive (PET+) | 69 (39, 91) | 69 (49, 85) | 50 (26, 74) | 83 (63, 95) | 0.69 (0.54, 0.85) |
LGE presence | 100 (75, 100) | 31 (15, 51) | 39 (23, 58) | 100 (66, 100) | 0.66 (0.66, 0.74) |
High native T1 | 100 (75, 100) | 39 (22, 59) | 43 (26, 63) | 100 (72, 100) | 0.70 (0.60, 0.79) |
High ECV | 100 (75, 100) | 39 (22, 59) | 43 (26, 63) | 100 (72, 100) | 0.70 (0.60, 0.79) |
High native T2 | 46 (19, 75) | 79 (59, 92) | 50 (21, 79) | 76 (57, 90) | 0.62 (0.46, 0.78) |
Updated Lake Louise criteria | 46 (19, 75) | 79 (59, 92) | 50 (21, 79) | 76 (57, 90) | 0.62 (0.46, 0.78) |
MRI positive (MRI+) | 100 (75, 100) | 31 (15, 51) | 39 (23, 58) | 100 (66, 100) | 0.66 (0.66, 0.74) |
Combined PET/MRI (PET+ and/or MRI+) | 100 (75, 100) | 28 (13, 47) | 38 (22, 56) | 100 (63, 100) | 0.64 (0.56, 0.72) |
Co-localized focal FDG uptake and LGE | 69 (39, 91) | 76 (57, 90) | 56 (30, 80) | 85 (65, 96) | 0.73 (0.57, 0.88) |
Co-localized focal FDG uptake and high T1 | 69 (39, 91) | 76 (57, 90) | 56 (30, 80) | 85 (65, 96) | 0.73 (0.57, 0.88) |
Co-localized focal FDG uptake and high T2 | 46 (19, 75) | 83 (64, 94) | 55 (23, 83) | 77 (59, 90) | 0.65 (0.49, 0.80) |
Patients not treated with immune suppression therapy (n = 36) | |||||
FDG-PET positive (PET+) | 73 (39, 94) | 72 (51, 88) | 53 (27, 79) | 86 (64, 97) | 0.72 (0.56, 0.89) |
LGE presence | 100 (72, 100) | 32 (15, 54) | 39 (22, 59) | 100 (63, 100) | 0.66 (0.57, 0.75) |
High native T1 | 100 (72, 100) | 38 (15, 54) | 39 (22, 59) | 100 (63, 100) | 0.66 (0.57, 0.75) |
High ECV | 100 (72, 100) | 38 (15, 54) | 39 (22, 59) | 100 (63, 100) | 0.66 (0.57, 0.75) |
High native T2 | 46 (17, 77) | 75 (53, 90) | 46 (17, 77) | 75 (53, 90) | 0.60 (0.42, 0.78) |
Updated Lake Louise criteria | 46 (17, 77) | 75 (53, 90) | 46 (17, 77) | 75 (53, 90) | 0.60 (0.42, 0.78) |
MRI positive (MRI+) | 100 (72, 100) | 24 (9, 45) | 37 (20, 56) | 100 (54, 100) | 0.62 (0.54, 0.71) |
Combined PET/MRI (PET+ and/or MRI+) | 100 (72, 100) | 28 (12, 49) | 38 (21, 58) | 100 (59, 100) | 0.64 (0.55, 0.73) |
Co-localized focal FDG uptake and LGE | 73 (39, 94) | 76 (55, 91) | 57 (29, 82) | 86 (65, 97) | 0.74 (0.58, 0.91) |
Co-localized focal FDG uptake and high T1 | 73 (39, 94) | 76 (55, 91) | 57 (29, 82) | 86 (65, 97) | 0.74 (0.58, 0.91) |
Co-localized focal FDG uptake and high T2 | 46 (17, 77) | 80 (59, 93) | 50 (19, 81) | 77 (56, 91) | 0.63 (0.45, 0.80) |